Last update 21 Jun 2024

Narlumosbart

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-RANKL Monoclonal Antibody(Jinmante Biological), Naloxumab, narlumosbart
+ [7]
Target
Mechanism
RANKL inhibitors(Tumor necrosis factor ligand superfamily member 11 inhibitors)
Inactive Indication
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
CN (05 Sep 2023),
RegulationPriority Review (CN), Conditional marketing approval (CN)
Login to view First Approval Timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Giant Cell Tumor of Bone
CN
05 Sep 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Bone metastasesPhase 3-05 Apr 2024
Malignant Solid NeoplasmPhase 3
CN
23 Jan 2024
Glucocorticoid-induced osteoporosisPhase 2
CN
15 Jun 2022
Osteoporosis, PostmenopausalPhase 2
CN
09 Mar 2022
Cardiomyopathy, HypertrophicPhase 2-24 Jan 2020
Humoral Hypercalcemia of MalignancyPhase 2-24 Jan 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
Bone Diseases
creatinine-adjusted urinary N-telopeptide (uNTx/Cr)
295
rrinaiwial(lnftlsawkp) = qybcwokewq naaiihnfjr (sxrjockcky )
Positive
24 May 2024
rrinaiwial(lnftlsawkp) = gdpcqugjdf naaiihnfjr (sxrjockcky )
Phase 1/2
-
tbmxfuvufz(nhchetowrp) = JMT103 group had 1 subject with adverse event (allergic dermatitis, CTCAE grade 2), which was considered related to the study drug and recovered after drug treatment. yqostxfmjw (xqpdrtvarz )
-
21 Sep 2022
Phase 1
59
(dose-escalation)
tnyucwqfrm(zskowjvybs) = No treatment-related serious adverse events were reported. qdlbxveesa (twktmkbvka )
Positive
05 Aug 2022
(dose-expansion)
Phase 1/2
38
lkaawloisv(dyabpjaibn) = wzapunbzzb yxyhngcujp (tpnxodypyl )
Positive
28 May 2021
Phase 1
56
nrvoxbqoja(yjmxbzwixj) = hypophosphatemia (n = 15), hypocalcemia (n = 12), and hypermagnesemia (n = 6) spuqxkysjr (lxkfenrdzx )
Positive
25 May 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free